{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001754386,0.0005712779,0.003454539,0.0006037645,0.00009170658,0.0000152695,0.0005811885,0.0002320495,0.002413876],"category_scores_gemma":[0.0006017924,0.0003093073,0.00009072282,0.001937135,0.001544417,0.0002314992,0.0001129563,0.001307926,0.000003431759],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002055371,"about_ca_system_score_gemma":0.008274933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002168591,"about_ca_topic_score_gemma":0.01546922,"domain_scores_codex":[0.992877,0.001891539,0.001518946,0.0009169558,0.001900001,0.0008955742],"domain_scores_gemma":[0.9952764,0.002699392,0.0004925244,0.000636412,0.0005379254,0.0003573463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7128524,0.008599777,0.006803533,0.0002867294,0.00100785,0.0002279644,0.002670113,0.0001389764,0.00000275156,0.00005858612,0.00001866404,0.2673327],"study_design_scores_gemma":[0.9510641,0.03041961,0.005763474,0.001955549,0.0006645918,0.00004640246,0.003773734,0.004616681,0.00004140269,0.0001113405,0.001172719,0.0003704306],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814369,0.001982268,0.002463116,0.002405763,0.0006248378,0.01037361,0.00005618976,0.00005862646,0.0005986894],"genre_scores_gemma":[0.9916603,0.003212583,0.001014346,0.001075816,0.00007546773,0.00251456,0.00002778434,0.00007048679,0.0003486375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2669623,"threshold_uncertainty_score":0.9999359,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03195292858781053,"score_gpt":0.4375393702416746,"score_spread":0.405586441653864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}